Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Bertagnolli Monica reported acquisition or exercise transactions in this Form 4 filing.
Natera, Inc. director Monica Bertagnolli reported two stock-based compensation grants. She received 75 restricted stock units (RSUs) that will vest in full on June 11, 2027, or sooner if Natera undergoes a change in control. She also received 1,571 RSUs issued in lieu of quarterly board retainer fees of $16,875, which were fully vested at issuance. Each RSU represents the right to receive one share of Natera common stock, increasing her equity-based compensation without an open-market stock purchase.
Baynes Roy D. reported acquisition or exercise transactions in this Form 4 filing.
Natera, Inc. director Roy D. Baynes reported receiving equity compensation in the form of restricted stock units (RSUs). One grant covers 75 RSUs that will vest in full on June 11, 2027, with full vesting also triggered if the company undergoes a change in control.
A separate award of 1,571 RSUs was issued in lieu of cash quarterly retainer fees of $16,875 for board service and was fully vested at issuance. Each RSU represents a contingent right to receive one share of Natera’s common stock, aligning a portion of director compensation with future share value.
Natera, Inc. reported that its Secretary and Chief Legal Officer, Daniel Rabinowitz, sold a total of 33,600 shares of Common Stock in open-market transactions on June 24, 2026. The sales were executed at weighted average prices between about $250 and $253 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025. Following these transactions, Rabinowitz directly holds 189,094 shares of Natera Common Stock.
Natera, Inc. director Herm Rosenman reported an open-market sale of 16,530 shares of Natera common stock on June 24, 2026 at $250.00 per share. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. Following this sale, Rosenman directly holds 4,250 shares of Natera common stock.
Daniel Rabinowitz submitted a Form 144 reporting proposed sales of Common Stock and disclosing recent 10b5-1 dispositions. Recent reported dispositions include 8,400 shares on 04/01/2026 for $1,707,814.08, 1,861 shares on 04/27/2026 for $379,811.07, and 330 shares on 05/01/2026 for $68,032.80.
The filing also lists 22,398 Restricted Stock Units (03/27/2024) and 11,202 previously exercised stock options (01/14/2022) as securities to be sold.
Natera, Inc. director and co-founder Sheena Jonathan reported pre-planned sales of company stock by family trusts. On June 17, 2026, Caraluna 1 and Caraluna 2 Trusts together sold 1,500 shares of Natera common stock in a series of open-market transactions under a Rule 10b5-1 trading plan adopted on June 7, 2024. The sales were executed at weighted average prices around the low- to mid-$220 per share range, based on multiple trades within narrow price bands. After these transactions, Jonathan continues to report 249,352 shares held directly, while Caraluna 1 Trust holds 19,276 shares and Caraluna 2 Trust holds 19,265 shares. The filing notes the trusts hold shares for their beneficiaries and that Jonathan disclaims beneficial ownership of the trust-held securities.
Natera, Inc. director Rowan E. Chapman sold shares in an open-market transaction. On June 16, 2026, Chapman sold 2,964 shares of Natera common stock at an average price of $216.78 per share.
Following the sale, Chapman directly held 3,124 Natera shares. The filing notes that this transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025, indicating it was scheduled in advance rather than timed discretionarily.
Natera, Inc. director and co-founder Sheena Jonathan reported open-market sales of the company’s common stock. On June 15, 2026, she sold a total of 3,150 shares in several transactions at prices around $210–$214 per share, as reflected by weighted average prices in the filing.
The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025, indicating they were scheduled in advance. Following these transactions, Jonathan holds 249,352 shares of Natera common stock directly. Additional shares are held indirectly through the Caraluna 1 and Caraluna 2 Trusts for the benefit of trust beneficiaries, and she disclaims beneficial ownership of those securities.
Natera, Inc. executive chairman Matthew Rabinowitz reported open-market sales of a total of 100,000 shares of common stock. The transactions took place on June 12 and June 15, 2026 at weighted average prices within ranges from $208.88 to $219.98 per share, according to accompanying footnotes.
The filing states that these sales were effected under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026. Following the transactions, Rabinowitz directly holds 2,277,843 common shares, with an additional 5,000 shares held indirectly by his spouse, indicating he retains a substantial equity position in the company.